IL134271A0 - Combinations of hmg-coa reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night - Google Patents
Combinations of hmg-coa reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at nightInfo
- Publication number
- IL134271A0 IL134271A0 IL13427198A IL13427198A IL134271A0 IL 134271 A0 IL134271 A0 IL 134271A0 IL 13427198 A IL13427198 A IL 13427198A IL 13427198 A IL13427198 A IL 13427198A IL 134271 A0 IL134271 A0 IL 134271A0
- Authority
- IL
- Israel
- Prior art keywords
- nicotinic acid
- nicotinamide
- methyl
- hmg
- combinations
- Prior art date
Links
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title abstract 7
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title abstract 2
- 208000031226 Hyperlipidaemia Diseases 0.000 title 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title 1
- 239000011664 nicotinic acid Substances 0.000 abstract 4
- 229960003512 nicotinic acid Drugs 0.000 abstract 4
- 235000001968 nicotinic acid Nutrition 0.000 abstract 3
- -1 6-OH-nicotinamide Chemical compound 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- IMRLNFKFNFLWQF-IYKITFJXSA-N sorbinicate Chemical compound O([C@H](COC(=O)C=1C=NC=CC=1)[C@@H](OC(=O)C=1C=NC=CC=1)[C@H](OC(=O)C=1C=NC=CC=1)[C@H](COC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 IMRLNFKFNFLWQF-IYKITFJXSA-N 0.000 abstract 2
- 206010072268 Drug-induced liver injury Diseases 0.000 abstract 1
- 208000021642 Muscular disease Diseases 0.000 abstract 1
- 201000009623 Myopathy Diseases 0.000 abstract 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 abstract 1
- KTLRWTOPTKGYQY-UHFFFAOYSA-N N-methyl-4-pyridone-3-carboxamide Chemical compound CN1C=CC(=O)C(C(N)=O)=C1 KTLRWTOPTKGYQY-UHFFFAOYSA-N 0.000 abstract 1
- ZYVXHFWBYUDDBM-UHFFFAOYSA-N N-methylnicotinamide Chemical compound CNC(=O)C1=CC=CN=C1 ZYVXHFWBYUDDBM-UHFFFAOYSA-N 0.000 abstract 1
- KUEUWHJGRZKESU-UHFFFAOYSA-N Niceritrol Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)(COC(=O)C=1C=NC=CC=1)COC(=O)C1=CC=CN=C1 KUEUWHJGRZKESU-UHFFFAOYSA-N 0.000 abstract 1
- USSFUVKEHXDAPM-UHFFFAOYSA-N Nicotinamide N-oxide Chemical compound NC(=O)C1=CC=C[N+]([O-])=C1 USSFUVKEHXDAPM-UHFFFAOYSA-N 0.000 abstract 1
- 206010039020 Rhabdomyolysis Diseases 0.000 abstract 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229940056243 aluminium nicotinate Drugs 0.000 abstract 1
- NSFYKDVWNTWJOK-UHFFFAOYSA-K aluminum;pyridine-3-carboxylate Chemical compound [Al+3].[O-]C(=O)C1=CC=CN=C1.[O-]C(=O)C1=CC=CN=C1.[O-]C(=O)C1=CC=CN=C1 NSFYKDVWNTWJOK-UHFFFAOYSA-K 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 238000013265 extended release Methods 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229960000827 niceritrol Drugs 0.000 abstract 1
- NPORIZAYKBQYLF-LREBCSMRSA-N nicotinyl alcohol tartrate Chemical compound OCC1=CC=CN=C1.OC(=O)[C@H](O)[C@@H](O)C(O)=O NPORIZAYKBQYLF-LREBCSMRSA-N 0.000 abstract 1
- 229960000839 nicotinyl alcohol tartrate Drugs 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 229950007581 sorbinicate Drugs 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90375297A | 1997-07-31 | 1997-07-31 | |
| PCT/US1998/015990 WO1999006035A2 (en) | 1997-07-31 | 1998-07-31 | COMBINATIONS OF HMG-CoA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL134271A0 true IL134271A0 (en) | 2001-04-30 |
Family
ID=25418027
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13427198A IL134271A0 (en) | 1997-07-31 | 1998-07-31 | Combinations of hmg-coa reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night |
| IL134271A IL134271A (en) | 1997-07-31 | 2000-01-27 | Pharmaceutical compositions for altering lipids comprising nicotinic acid compounds and hmg-coa reductase inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL134271A IL134271A (en) | 1997-07-31 | 2000-01-27 | Pharmaceutical compositions for altering lipids comprising nicotinic acid compounds and hmg-coa reductase inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20040053975A1 (es) |
| EP (2) | EP1017390B1 (es) |
| JP (2) | JP4870869B2 (es) |
| AT (2) | ATE451926T1 (es) |
| AU (1) | AU752673B2 (es) |
| BR (1) | BR9815548A (es) |
| CA (1) | CA2298549C (es) |
| CY (1) | CY1107057T1 (es) |
| DE (2) | DE69841395D1 (es) |
| DK (1) | DK1017390T3 (es) |
| ES (2) | ES2283067T3 (es) |
| IL (2) | IL134271A0 (es) |
| NO (1) | NO20000439L (es) |
| NZ (1) | NZ520176A (es) |
| PT (1) | PT1017390E (es) |
| WO (1) | WO1999006035A2 (es) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE970731A1 (en) † | 1997-10-07 | 2000-10-04 | Fuisz Internat Ltd | Product and method for the treatment of hyperlipidemia |
| DE19858789A1 (de) * | 1998-12-18 | 2000-06-21 | Bayer Ag | Kombination von Cerivastatin und Fibraten |
| US6569461B1 (en) | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
| AU774636B2 (en) * | 1999-07-14 | 2004-07-01 | Genzyme Corporation | Fat-binding polymers, optionally combined with lipase inhibitors |
| JP2001131151A (ja) * | 1999-11-02 | 2001-05-15 | Shionogi & Co Ltd | オレフィン誘導体の新規用途 |
| IL139450A0 (en) * | 1999-11-10 | 2001-11-25 | Pfizer Prod Inc | Methods of administering apo b-secretion/mtp inhibitors |
| CZ20024015A3 (cs) † | 2000-06-09 | 2003-04-16 | Lek Pharmaceutical D.D. | Stabilní farmaceutický produkt a jeho formulace |
| US6916849B2 (en) | 2000-10-23 | 2005-07-12 | Sankyo Company, Limited | Compositions for improving lipid content in the blood |
| CN1250212C (zh) * | 2000-10-23 | 2006-04-12 | 三共株式会社 | 血中脂类改善剂组合物 |
| CA2428204A1 (en) * | 2000-11-07 | 2002-05-16 | Sankyo Company, Limited | Lipid peroxide-lowering compositions |
| TWI284529B (en) * | 2000-12-18 | 2007-08-01 | Sankyo Co | A composition for lowering triglyceride |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| IL156445A0 (en) | 2001-01-26 | 2004-01-04 | Schering Corp | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| AR035533A1 (es) | 2001-01-26 | 2004-06-02 | Schering Corp | Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| MXPA04002573A (es) | 2001-09-21 | 2004-06-18 | Schering Corp | Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol. |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| ITMI20012366A1 (it) * | 2001-11-09 | 2003-05-09 | Farmatron Ltd | Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali |
| US7176310B1 (en) | 2002-04-09 | 2007-02-13 | Ucb Sa | Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents |
| AU2003252358A1 (en) * | 2002-08-02 | 2004-02-23 | Sankyo Company, Limited | MEDICINAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR |
| JP4607436B2 (ja) * | 2002-08-02 | 2011-01-05 | 第一三共株式会社 | ＨＭＧ−ＣｏＡリダクターゼ阻害剤を含有する医薬組成物 |
| CN100415235C (zh) * | 2002-08-02 | 2008-09-03 | 三共株式会社 | 含有HMG-CoA还原酶抑制剂的药物组合物 |
| WO2004043457A1 (en) | 2002-11-06 | 2004-05-27 | Schering Corporation | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| SI21402A (sl) | 2003-02-12 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Obloženi delci in farmacevtske oblike |
| EP1601668B1 (en) | 2003-03-07 | 2008-08-27 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| CA2517572C (en) | 2003-03-07 | 2011-12-13 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| JP2006519869A (ja) | 2003-03-07 | 2006-08-31 | シェーリング コーポレイション | 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用 |
| AR041089A1 (es) * | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
| EP1653926A1 (en) * | 2003-08-04 | 2006-05-10 | Pfizer Products Inc. | Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| WO2005041878A2 (en) * | 2003-10-29 | 2005-05-12 | Tawakol Raif M D | Compositions and methods for increasing hdl and hdl-2b levels |
| US20060229265A1 (en) * | 2005-03-30 | 2006-10-12 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
| US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| US20060292099A1 (en) * | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
| US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| AU2006329564A1 (en) * | 2005-07-11 | 2007-07-05 | Pharmena North America Inc. | Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative |
| KR20070063350A (ko) * | 2005-12-14 | 2007-06-19 | 주식회사종근당 | 서방형 방출층과 속방형 방출층을 포함한 고지혈증 및동맥경화를 치료를 위한 약제학적 조성물 |
| CA2569776A1 (en) * | 2006-02-17 | 2007-08-17 | Kos Life Sciences, Inc. | Low flush niacin formulation |
| EP2081550B2 (en) * | 2006-03-09 | 2021-05-26 | Reliant Pharmaceuticals, Inc. | Coating capsules with active pharmaceutical ingredients |
| US8784886B2 (en) | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
| WO2008023958A1 (en) * | 2006-08-24 | 2008-02-28 | Hanall Pharmaceutical Co., Ltd. | Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors |
| WO2008023869A1 (en) * | 2006-08-24 | 2008-02-28 | Hanall Pharmaceutical Co., Ltd. | Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors |
| DE102007003524A1 (de) * | 2007-01-19 | 2008-09-04 | MEDICE Arzneimittel Pütter GmbH & Co. KG | Arzneimittel zur Behandlung und/oder Prävention von Arteriosklerose |
| KR100885029B1 (ko) | 2007-02-07 | 2009-02-23 | 지엘팜텍 주식회사 | 경구투여용 서방성 삼중정제 |
| WO2009016577A2 (en) * | 2007-07-27 | 2009-02-05 | Ranbaxy Laboratories Limited | A pharmaceutical composition comprising atorvastatin and niacin |
| EP2255796A2 (en) * | 2008-02-22 | 2010-12-01 | HanAll Biopharma Co., Ltd. | Pharmaceutical preparation |
| JP2011512406A (ja) * | 2008-02-22 | 2011-04-21 | ハナル バイオファーマ カンパニー リミテッド | 複合製剤 |
| KR20090091075A (ko) * | 2008-02-22 | 2009-08-26 | 한올제약주식회사 | 심혈관계 질환 치료용 약제학적 제제 |
| BRPI0912842A8 (pt) * | 2008-05-20 | 2019-01-29 | Cerenis Therapeutics Holding | composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina |
| MX2010013169A (es) * | 2008-06-02 | 2010-12-21 | Reddy S Lab Ltd | Formulaciones de niacina de liberacion modificada. |
| RU2010153904A (ru) * | 2008-06-02 | 2012-07-20 | Др. Редди'С Лабораторис Лтд. (In) | Ниацин-содержащие композиции с модифицированным высвобождением |
| US20100178341A1 (en) * | 2008-06-11 | 2010-07-15 | Ranbaxy Laboratories Limited | BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR |
| US8541435B2 (en) | 2008-07-11 | 2013-09-24 | Uday Saxena | Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of Alzheimer's disease (AD) |
| JP5845172B2 (ja) * | 2009-05-01 | 2016-01-20 | アデア ファーマスーティカルズ，インコーポレイテッド | 高および低用量薬物の組み合わせを含む口腔内崩壊錠組成物 |
| CA2706270C (en) | 2010-06-03 | 2020-01-07 | Accucaps Industries Limited | Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation |
| CA2835364C (en) | 2011-05-20 | 2018-10-02 | Astrazeneca Uk Limited | Pharmaceutical composition of rosuvastatin calcium |
| WO2016077832A2 (en) | 2014-11-14 | 2016-05-19 | Gemphire Therapeutics Inc. | PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS |
| AU2016348638A1 (en) * | 2015-11-06 | 2018-06-07 | Gemphire Therapeutics Inc. | Gemcabene combinations for the treatment of cardiovascular disease |
| EP3612171A4 (en) | 2017-04-18 | 2020-10-21 | Gemphire Therapeutics Inc. | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3524001A (en) * | 1965-03-04 | 1970-08-11 | Upjohn Co | Compositions and method for reducing free fatty acid and cholesterol in the blood of mammals with 3,5 - disubstituted isoxazoles |
| JPS63310827A (ja) * | 1987-06-15 | 1988-12-19 | Sanwa Kagaku Kenkyusho Co Ltd | ニコチン酸誘導体を主剤とする徐放性製剤 |
| US5260305A (en) * | 1988-12-12 | 1993-11-09 | E. R. Squibb & Sons, Inc. | Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination |
| US4933165A (en) * | 1989-01-18 | 1990-06-12 | Merck & Co., Inc. | Coenzyme Q10 with HMG-CoA reductase inhibitors |
| US5268181A (en) * | 1989-04-13 | 1993-12-07 | Upsher-Smith Laboratories, Inc. | Method of using niacin to control nocturnal cholesterol synthesis |
| CA2016467A1 (en) * | 1989-06-05 | 1990-12-05 | Martin Eisman | Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor |
| CA2018470A1 (en) * | 1989-07-17 | 1991-01-17 | Scott Adams Biller | Phosphorus-containing squalene synthetase inhibitors and method |
| US5591772A (en) * | 1991-11-22 | 1997-01-07 | Lipogenics, Inc. | Tocotrienols and tocotrienol-like compounds and methods for their use |
| US5135935A (en) * | 1991-05-17 | 1992-08-04 | Merck & Co., Inc. | Squalene synthetase inhibitors |
| US5840339A (en) * | 1991-07-30 | 1998-11-24 | Kunin; Robert | Blood cholesterol reducing pharmaceutical composition |
| US5292534A (en) * | 1992-03-25 | 1994-03-08 | Valentine Enterprises, Inc. | Sustained release composition and method utilizing xanthan gum and an active ingredient |
| US5609884A (en) * | 1992-08-31 | 1997-03-11 | G. D. Searle & Co. | Controlled release naproxen sodium plus naproxen combination tablet |
| US6080428A (en) * | 1993-09-20 | 2000-06-27 | Bova; David J. | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
| US6129930A (en) * | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
| US6369103B1 (en) * | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
| US5582838A (en) * | 1994-12-22 | 1996-12-10 | Merck & Co., Inc. | Controlled release drug suspension delivery device |
| US5773453A (en) * | 1995-04-19 | 1998-06-30 | Vanderbilt University | Methods for administration of antilipemic drugs |
| AU5787996A (en) * | 1995-04-19 | 1996-11-07 | Lipoprotein Technologies, Inc. | Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs |
-
1998
- 1998-07-31 DK DK98938228T patent/DK1017390T3/da active
- 1998-07-31 EP EP98938228A patent/EP1017390B1/en not_active Expired - Lifetime
- 1998-07-31 ES ES98938228T patent/ES2283067T3/es not_active Expired - Lifetime
- 1998-07-31 DE DE69841395T patent/DE69841395D1/de not_active Expired - Lifetime
- 1998-07-31 ES ES07003276T patent/ES2336492T3/es not_active Expired - Lifetime
- 1998-07-31 NZ NZ520176A patent/NZ520176A/en not_active IP Right Cessation
- 1998-07-31 WO PCT/US1998/015990 patent/WO1999006035A2/en not_active Ceased
- 1998-07-31 AU AU86801/98A patent/AU752673B2/en not_active Ceased
- 1998-07-31 DE DE69837610T patent/DE69837610T2/de not_active Expired - Lifetime
- 1998-07-31 EP EP07003276A patent/EP1792616B1/en not_active Expired - Lifetime
- 1998-07-31 AT AT07003276T patent/ATE451926T1/de not_active IP Right Cessation
- 1998-07-31 IL IL13427198A patent/IL134271A0/xx active IP Right Grant
- 1998-07-31 BR BR9815548-2A patent/BR9815548A/pt not_active Application Discontinuation
- 1998-07-31 JP JP2000504849A patent/JP4870869B2/ja not_active Expired - Fee Related
- 1998-07-31 CA CA002298549A patent/CA2298549C/en not_active Expired - Lifetime
- 1998-07-31 PT PT98938228T patent/PT1017390E/pt unknown
- 1998-07-31 AT AT98938228T patent/ATE359785T1/de active
-
2000
- 2000-01-27 IL IL134271A patent/IL134271A/en not_active IP Right Cessation
- 2000-01-27 NO NO20000439A patent/NO20000439L/no not_active Application Discontinuation
-
2003
- 2003-09-02 US US10/260,027 patent/US20040053975A1/en not_active Abandoned
-
2007
- 2007-05-07 CY CY20071100604T patent/CY1107057T1/el unknown
-
2009
- 2009-02-27 US US12/394,441 patent/US20090226518A1/en not_active Abandoned
- 2009-07-22 JP JP2009170721A patent/JP2009235105A/ja active Pending
-
2011
- 2011-10-27 US US13/282,755 patent/US20120164221A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999006035A3 (en) | 1999-04-22 |
| ES2283067T3 (es) | 2007-10-16 |
| CY1107057T1 (el) | 2012-10-24 |
| DE69837610T2 (de) | 2008-01-03 |
| DE69837610D1 (de) | 2007-05-31 |
| CA2298549A1 (en) | 1999-02-11 |
| IL134271A (en) | 2006-07-05 |
| NZ520176A (en) | 2005-02-25 |
| JP4870869B2 (ja) | 2012-02-08 |
| AU752673B2 (en) | 2002-09-26 |
| DK1017390T3 (da) | 2007-06-11 |
| EP1792616B1 (en) | 2009-12-16 |
| ES2336492T3 (es) | 2010-04-13 |
| US20120164221A1 (en) | 2012-06-28 |
| EP1792616A1 (en) | 2007-06-06 |
| US20040053975A1 (en) | 2004-03-18 |
| JP2001511444A (ja) | 2001-08-14 |
| ATE451926T1 (de) | 2010-01-15 |
| HK1106153A1 (en) | 2008-03-07 |
| BR9815548A (pt) | 2000-11-07 |
| ATE359785T1 (de) | 2007-05-15 |
| CA2298549C (en) | 2006-01-10 |
| US20090226518A1 (en) | 2009-09-10 |
| EP1017390A2 (en) | 2000-07-12 |
| NO20000439L (no) | 2000-03-22 |
| WO1999006035A2 (en) | 1999-02-11 |
| DE69841395D1 (de) | 2010-01-28 |
| AU8680198A (en) | 1999-02-22 |
| EP1017390B1 (en) | 2007-04-18 |
| NO20000439D0 (no) | 2000-01-27 |
| PT1017390E (pt) | 2007-07-24 |
| JP2009235105A (ja) | 2009-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL134271A0 (en) | Combinations of hmg-coa reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night | |
| AU5683296A (en) | N-benzylindol-3-yl propanic acid derivatives as cyclooxygena se-2 inhibitors | |
| NO973814L (no) | Basisk stabilisert sammensetning av HMG-CoA-reduktase inhibitor | |
| IE970731A1 (en) | Product and method for the treatment of hyperlipidemia | |
| CA2356158A1 (en) | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications | |
| AU7756694A (en) | Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals | |
| EP3363463A3 (en) | Hyaluronic acid derivative and drug containing the same | |
| HUT63328A (en) | Process for producing stabilized pharmaceutical compositions comprissing hmg-coa reductase inhibitor | |
| EP0773022A3 (de) | Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure | |
| IL134272A0 (en) | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia | |
| AU1022795A (en) | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor | |
| YU3199A (sh) | Antitrombični i antiaterogeni farmaceutski preparat koji obuhvata derivat tienopiridina i inhibitor hmg-c | |
| AU3368400A (en) | Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammationassociated with pulmonary disease | |
| AU6527090A (en) | Substituted cyclohexene derivatives as hmg-coa reductase inhibitors | |
| AU7370096A (en) | Bis-heteroarylylmethoxyphenylketone derivatives as inhibitors of leukotriene biosynthesis | |
| KR970706807A (ko) | 메티오날 또는 말론디알데히드의 세포 내 비율에 영향을 미치는 성분을 함유하는 세포소멸(Capoptosis) 조절 조성물(APOPTOSIS-MODULATING COMPOSITION COMPRISING A FACTOR AFFECTING THE INTRACELLULAR RATE OF METHIONAL OR MALONDIALDEHYDE) | |
| BR0317520A (pt) | Composições de inibidores de proteìna de transferência de ésteres de colesterilo e inibidores de hmg-coa redutase | |
| AU4543699A (en) | Multibinding inhibitors of hmg-coa reductase | |
| TW355709B (en) | Quinoline carboxylic acid derivative | |
| AU645287B2 (en) | Quinoline and pyridine anchors for HMG-CoA reductase inhibitors | |
| AU637321B2 (en) | Quinoline and pyridine anchors for a hmg-coa reductase inhibitors | |
| AU4856996A (en) | Crystalline composition of lysine and succinic acid or alkali metal salt thereof | |
| AU7654200A (en) | Phthalazinone derivatives as pd3/4 inhibitors | |
| AU1289792A (en) | Aminosteroids in a method for inhibiting c17-20 lyase | |
| NO20053581L (no) | Optisk aktivt dihydropyridinderivat. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |